CEACAM5 and lung carcinoma: Similarly, primary EGFR‐mutated lung cancer cells (MGH119) showed higher CEACAM5 and epithelial marker CLDN1 expression but lower mesenchymal marker CDH2 expression than their EGFR‐TKI gefitinib‐resistant counterparts (MGH119GR) (Figure 4B).